Results from a phase 2b clinical trial published in Nature Medicine show that aleniglipron, an experimental oral, small-molecule GLP-1 receptor agonist, produced weight loss of up to 12.1% of body weight over 36 weeks at its highest tested dose, compared with a 0.5% change in the placebo group.
Across the trial's dose groups, body weight change from baseline ranged from -9.0% at 45 milligrams to -12.1% at 120 milligrams. Researchers reported gastrointestinal side effects that were generally mild to moderate and decreased in frequency over the course of the study, with no reported cases of drug-induced liver injury and a 10.4% overall discontinuation rate across groups.
Unlike currently marketed peptide-based GLP-1 drugs such as semaglutide, which require injection and cold-chain storage, aleniglipron is taken orally and can be manufactured at larger scale -- a distinction study co-author Robert Kushner, MD, said could help address longstanding accessibility and cost barriers for GLP-1 treatment.
The findings support moving into a phase III trial, researchers said, with a slower dose-escalation schedule planned to improve tolerability further.
As oral options move through the pipeline, the core planning questions for anyone considering treatment stay the same regardless of drug format -- what a realistic timeline looks like, and what happens to weight after stopping. Our Weight Loss Reality Simulator models both.
Sources: Medical Xpress, Northwestern Feinberg School of Medicine